Bruker Corporation · NASDAQ:BRKR

Bruker — Barclays Global Healthcare Conference 2019

13 slides from Bruker's conference presentation, Mar 14, 2019

  1. Slide 1: Bruker Corporation (Nasdaq: BRKR)

    Bruker Corporation (Nasdaq: BRKR) Bruker drives customer success and profitable growth by enabling scientific discoveries and delivering high-performance analytical, life science, pharmaceutical and diagnostic solutions. Innovation with Integrity © Bruker Corporation

  2. Slide 2: Safe Harbor Statement

    Bruker Corporation Safe Harbor Statement Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Security Exchange Act of 1934, as

  3. Slide 3: Bruker Overview

    Bruker Overview Differentiated Leader in Attractive, Diverse Life Science and Diagnostic Tools Markets Bruker revenue breakdown, % of LTM revenue(1): BIOSPIN Group NANO Group Europe • Founded in 1960, Bruker brand stands Magnetic Resonance: Advanced X-Ray for innovation NMR, EPR, Atomic Force Micros

  4. Slide 4: Key Objectives for 2019-2023

    Bruker Key Objectives for 2019-2023 1. Accelerate revenue growth • Enhance organic revenue growth with Project Accelerate initiatives Proteomics & Phenomics After-Market Biopharma & Applied 2. Transform portfolio with six high-growth, high-margin Project Accelerate initiatives Next-gen Nanotech Micr

  5. Slide 5: Portfolio Transformation

    Portfolio Transformation Portfolio Reshaping our portfolio for faster growth and higher margins* 2018 2019E 2020E 2021E 2022E 2023E Proteomics & timsTOF Pro Proteomics, 1.0 GHz NMR Phenomics Mass spec based Phenomics, 1.2 GHz NMR Advanced NMR and mass spec solutions for biologics and small molecule

  6. Slide 6: 2015 to 2018 Financials

    Bruker 2015 to 2018 Financials Accelerating revenue growth and healthy margin expansion drive EPS Revenue Non-GAAP Operating Margin(1) Non-GAAP EPS(1) $1.90B 16.8% $1.40 $1.77B 15.9% 15.0% $1.19 $1.21 $1.62B $1.61B 13.5% $0.89 FY 2015 FY2016 FY 2017 FY 2018 FY 2015 FY2016 FY 2017 FY 2018 FY 2015 FY2

  7. Slide 7: FY 2019 Guidance: Further organic revenue growth and operating margin improvement, solid EPS growth

    FY 2019 Guidance: Further organic revenue growth and operating margin improvement, solid EPS growth FY 2019 Guidance 2019 ASSUMPTIONS  Organic revenue growth: +4% to +5% Revenue Growth y-o-y +6% to +7%  Acquisition revenue growth: approximately +4%  Constant currency revenue growth: Non-GAAP Oper

  8. Slide 8: www.bruker.com

    www.bruker.com © Bruker Corporation 8

  9. Slide 9: Reconciliation of Non-GAAP Operating Income and EPS

    Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (unaudited) (in millions, except per share amounts) Twelve Months Ended December 31, 2015 (1) 2016 (1) 2017 (1) 2018 Reconciliation of Non-GAAP Operating Income, Non-GAAP Profit Before Tax, Non-GAAP Net Income, and Non-GAAP EPS

  10. Slide 10: Reconciliation of Non-GAAP Gross Profit and Tax Rate

    Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (Unaudited) (in millions, except per share amounts) Twelve Months Ended December 31, (1) 2015 2016 (1) 2017 (1) 2018 Reconciliation of GAAP and Non-GAAP Gross Profit GAAP Gross Profit $ 711.2 $ 745.3 $ 816.0 $ 900.0 Non-GAAP Ad

  11. Slide 11: Reconciliation of Non-GAAP Earnings Per Share

    Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (Unaudited) (in millions, except per share amounts) Twelve Months Ended December 31, (1) 2015 2016 (1) 2017 (1) 2018 Reconciliation of GAAP and Non-GAAP Earnings Per Share (Diluted) GAAP Earnings Per Share (Diluted) $ 0.60 $ 0.

  12. Slide 12: Reconciliation of Free Cash Flow and ROIC

    Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (Unaudited) (in millions, except per share amounts) Twelve Months Ended December 31, 2015 (1) 2016 (1) 2017 (1) 2018 Reconciliation of GAAP Operating Cash Flow and Non-GAAP Free Cash Flow GAAP Operating Cash Flow $ 229.2 $ 130.

  13. Slide 13: Reconciliation of Impact of Adoption of ASU 2017-07

    Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (Unaudited) (in millions, except per share amounts) Twelve Months Ended December 31, 2015 (1) 2016 (1) 2017 (1) 2018 (2) Reconciliation of Impact of Adoption of ASU 2017-07 Cost of revenues (2.6) (2.8) (3.0) (2.1) Selling, gene

Bruker — Barclays Global Healthcare Conference 2019 on 6ix